H
H. Lundbeck A/S (HLUBF)
PNK – Real vaqt narxi. Valyuta: USD
5.54
0.00 (0.00%)
Yopilishda: Sep 10, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
PNK – Real vaqt narxi. Valyuta: USD
5.54
0.00 (0.00%)
Yopilishda: Sep 10, 2026, 4:00 PM EDT
H. Lundbeck A/S kompaniyasi Yevropa, AQSh va xalqaro miqyosda ruhiy va nevrologik kasalliklarni davolash uchun farmatsevtika mahsulotlarini tadqiq qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirish bilan shug'ullanadi. Kompaniya kattalardagi shizofreniya va I turdagi bipolyar buzuqlikni davolash uchun Abilify Maintena/ Abilify Asimtufii; depressiv kasalliklarni davolash uchun Brintellix/Trintellix; katta depressiv buzuqlik va shizofreniyani davolash uchun Rexulti/Rxulti; migrenni oldini olish uchun Vyepti; va depressiyani davolash uchun Cipralex/Lexapro mahsulotlarini taklif etadi. Shuningdek, u simptomatik neyrogen ortostatik gipotoniya uchun Northera; epilepsiya uchun Onfi; refrakter kompleks parsial tutqanoqlar va infantil spazmlar uchun Sabril; demensiya uchun Ebixa, Parkinson kasalligi uchun Azilect; xoreya uchun Xenazine; depressiya uchun Deanxit; depressiya va tashvish uchun Cipramil; va psixoz uchun Cisordinolni taqdim etadi. Bundan tashqari, kompaniya migrenni oldini olish uchun Eptinezumab; klaster bosh og'rig'ini davolash bo'yicha 3-bosqich klinik sinovlarida bo'lgan Eptinezumab; migrenni oldini olish bo'yicha 2-bosqich klinik sinovlarida bo'lgan Lu AG09222; neyrogormonal disfunksiyani davolash bo'yicha 1-bosqich klinik sinovlarida bo'lgan Lu AG13909; posttravmatik stress buzilishini davolash uchun Brexpiprazole; Parkinson kasalligini davolash bo'yicha 1-bosqich klinik sinovlarida bo'lgan Lu AF28996; nevrologiya sohasida 1-bosqich klinik sinovlarida bo'lgan MAGLi dasturi; rivojlanish va epileptik ensefalopatiyalarni davolash bo'yicha 3-bosqich klinik sinovlarida bo'lgan Bexicaserin; sinukleinopatiyalarni davolash bo'yicha 3-bosqich klinik sinovlarida bo'lgan Amlenetug; va nevrologiya sohasida 1-bosqich klinik sinovlarda bo'lgan Lu AG22515 ni ishlab chiqmoqda. Lundbeck A/S kompaniyasi jiddiy nevrologik kasalliklari bo'lgan bemorlar uchun oligonukleotid asosidagi dori vositalarini ishlab chiqish bo'yicha Contera Pharma bilan strategik tadqiqot hamkorligiga ega. Kompaniya 1915 yilda tashkil etilgan va shtab-kvartirasi Daniyaning Valby shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Per Johan Luthman Ph.D. | Advisor |
| Jens Hoyer | Vice President & Head of Investor Relations |
| Mr. Charl van Zyl | President & CEO |
| Mr. Joerg Hornstein | CFO & Executive VP of Corporate Functions |
| Mr. Lars Bang | Executive Vice President of Product Development & Supply |
| Mr. Thomas E. Gibbs | Executive VP & Head of Lundbeck in United States |
| Sana | Turi | Hujjat |
|---|---|---|
| 2024-02-14 | F-6EF | e619275_f6ef-hl.htm |
| Ms. Dianne Holto |
| Executive Vice President of People, Culture & Sustainability |
| Ms. Michala Fischer-Hansen | Executive VP and Head of Europe & International Markets and Operations |
| Ms. Tine Ostergaard Hansen | Senior Vice President of Corporate Communications & Public Affairs |
| Prof. Johannes Rolf Streffer M.D. | Senior VP & Head of Global Clinical Development |